Investigational Drug Information for Eplivanserin
✉ Email this page to a colleague
What is the development status for investigational drug Eplivanserin?
Eplivanserin is an investigational drug.
There have been 7 clinical trials for Eplivanserin.
The most recent clinical trial was a Phase 3 trial, which was initiated on November 1st 2005.
The most common disease conditions in clinical trials are Sleep Initiation and Maintenance Disorders, Sleep Wake Disorders, and Parasomnias. The leading clinical trial sponsors are Sanofi and [disabled in preview].
Summary for Eplivanserin
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 580 |
| WIPO Patent Applications | 349 |
| Japanese Patent Applications | 43 |
| Clinical Trial Progress | Phase 3 (2005-11-01) |
| Vendors | 39 |
Recent Clinical Trials for Eplivanserin
| Title | Sponsor | Phase |
|---|---|---|
| Single Dose Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Evaluation of Eplivanserin in Children With Insomnia | Sanofi | Phase 1 |
| Efficacy and Safety of Eplivanserin 5mg/Day in Insomnia Characterized by Sleep Maintenance Difficulties | Sanofi | Phase 3 |
| Comparison of Eplivanserin and Lormetazepam in the Treatment of Insomnia Characterized by Sleep Maintenance Difficulties | Sanofi | Phase 3 |
Clinical Trial Summary for Eplivanserin
Top disease conditions for Eplivanserin
Top clinical trial sponsors for Eplivanserin
US Patents for Eplivanserin
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
